3.82
-0.29(-7.06%)
Currency In USD
| Previous Close | 4.11 |
| Open | 4.17 |
| Day High | 4.44 |
| Day Low | 3.81 |
| 52-Week High | 16.55 |
| 52-Week Low | 1.6 |
| Volume | 1.58M |
| Average Volume | 1.09M |
| Market Cap | 283.55M |
| PE | -3.11 |
| EPS | -1.23 |
| Moving Average 50 Days | 2.68 |
| Moving Average 200 Days | 5.51 |
| Change | -0.29 |
If you invested $1000 in Perspective Therapeutics, Inc. (CATX) 10 years ago, it would be worth $248.05 as of June 25, 2025 at a share price of $3.82. Whereas If you bought $1000 worth of Perspective Therapeutics, Inc. (CATX) shares 5 years ago, it would be worth $636.67 as of June 25, 2025 at a share price of $3.82.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
GlobeNewswire Inc.
Jun 21, 2025 12:00 PM GMT
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2Dosimetry sub-study analysis presented at the Society of Nuclear Medicine &
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
GlobeNewswire Inc.
Jun 21, 2025 12:00 PM GMT
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced two presentati
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
GlobeNewswire Inc.
May 30, 2025 9:21 PM GMT
Updated interim results with an additional ~16 weeks of follow-up on nine patients in Cohort 1 (2.5 mCi) and Cohort 2 (5.0 mCi) and initial safety findings in an additional 33 patients treated in Cohort 2 from the ongoing Phase 1/2a study were prese